Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: A pilot safety and effectiveness analysis in a small patient cohort

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16735-16745

  Chi, Kwan Hwa ^a,b   Ko, Hui Ling ^a   Yang, Kai Lin ^a   Lee, Cheng Yen ^a   Chi, Mau Shin ^a   Kao, Shang Jyh ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Autophagy; Hydroxychloroquine; Metronomic chemotherapy; Rapamycin

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; HYDROXYCHLOROQUINE; IRINOTECAN; METHOTREXATE; NAVELBINE; RAPAMYCIN; UFT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLADDER CANCER; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CARDIOTOXICITY; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEAD AND NECK CANCER; HEPATITIS B; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; PILOT STUDY; PROSTATE CANCER; RASH; RETINOPATHY; RETROSPECTIVE STUDY; SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; AUTOPHAGY; DOSE RESPONSE; DRUG EFFECTS; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, METRONOMIC; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PILOT PROJECTS; SALVAGE THERAPY; SIROLIMUS; TREATMENT OUTCOME;

EID: 84937857572     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3793     Document Type: Article

References (48)

1. Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V and Marchetti P. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer chemotherapy and pharmacology. 2013; 72:13-33.
2. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A and Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999; 94:4143-4155.
3. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landre J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM and Bikfalvi A. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer research. 2001; 61:7501-7506.
4. Hermans IF, Chong TW, Palmowski MJ, Harris AL and Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer research. 2003; 63:8408-8413.
5. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25:4722-4729.
6. Barber EL, Zsiros E, Lurain JR, Rademaker A, Schink JC and Neubauer NL. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. Journal of gynecologic oncology. 2013; 24:258-264.
7. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:4899-4905.
8. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, Custodio A, Casado A and Diaz-Rubio E. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxanerefractory breast cancer. Journal of chemotherapy. 2008; 20:632-639.
9. Marquette CL, Grant, S.C., DeShazo, M., Reddy, V., Cantor, A., Miley, D., Jerome, M., Robert, F. Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients with advanced nonsquamous non-small cell lung cancer (NSNSCLC). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31((supply)):abstr. 8057.
10. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C and Cheng AL. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of hepatology. 2010; 53:126-131.
11. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British journal of cancer. 2013; 109:1725-1734.
12. Mizushima N, Levine B, Cuervo AM and Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008; 451:1069-1075.
13. Yang ZJ, Chee CE, Huang S and Sinicrope FA. The Role of Autophagy in Cancer: Therapeutic Implications. Molecular Cancer Therapeutics. 2011; 10:1533-1541.
14. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ and Carew JS. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014; 10:1403-1414.
15. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014; 10:1391-1402.
16. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O'Dwyer PJ, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014; 10:1369-1379.
17. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014; 10:1380-1390.
18. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014; 10:1359-1368.
19. Poklepovic A and Gewirtz DA. Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. Autophagy. 2014; 10:1478-1480.
20. Vignot S, Faivre S, Aguirre D and Raymond E. mTORtargeted therapy of cancer with rapamycin derivatives. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2005; 16:525-537.
21. Seront E, Boidot R, Bouzin C, Karroum O, Jordan BF, Gallez B, Machiels JP and Feron O. Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours. British journal of cancer. 2013; 109:2597-2606.
22. Xie X, White EP and Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PloS one. 2013; 8:e55096.
23. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM and Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Science signaling. 2010; 3:ra81.
24. Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, Chen J, Chen H-Y, Ghavami A, Stein M, DiPaola RS, Zhang D, Rabinowitz JD and White E. Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition. PLoS ONE. 2012; 7:e41831.
25. Wang YS HY, Fong WL, Chi MS, Chi KH. Abstract 5611: A synthetic lethality combination with chloroquine and rapamycin on chemosensitization. Cancer research. 2012; 72(8 Supplement %U http://cancerres.aacrjournals.org/content/72/8_Supplement/5611.abstract):5611.
26. Grimaldi A, Balestrieri ML, D'Onofrio N, Di Domenico G, Nocera C, Lamberti M, Tonini G, Zoccoli A, Santini D, Caraglia M and Pantano F. The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence. PLoS ONE. 2013; 8:e79658.
27. Cancer Therapy Evaluation Program. NCI. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Data files and Related Documents. http://evsncinihgov/ftp1/CTCAE/Abouthtml. 2011; Accessed October 21.
28. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
29. Lencioni R and Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease. 2010; 30:52-60.
30. Bocci G, Nicolaou KC and Kerbel RS. Protracted lowdose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer research. 2002; 62:6938-6943.
31. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer research. 2003; 63:4342-4346.
32. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D and Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8:221-232.
33. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW and Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature medicine. 2002; 8:128-135.
34. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion AC, Radtke F, Boulanger C, et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer cell. 2014; 26:190-206.
35. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, PodoloffDA and Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25:1753-1759.
36. Mason WP, Macneil M, Kavan P, Easaw J, Macdonald D, Thiessen B, Urva S, Lwin Z, McIntosh L and Eisenhauer E. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Investigational new drugs. 2012; 30:2344-2351.
37. Sotelo J, Briceno E and Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Annals of internal medicine. 2006; 144:337-343.
38. Kim SJ, Kang HJ, Kim JS, Eom HS, Huh J, Ko YH, Lee J, Yim DS, Lee SY, Park WS, Yang WI, Lee SS, Suh C and Kim WS. A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. Investigational new drugs. 2013; 31:1514-1521.
39. Schuetze SM, Zhao L, Chugh R, Thomas DG, Lucas DR, Metko G, Zalupski MM and Baker LH. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. European journal of cancer. 2012; 48:1347-1353.
40. Andre F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. 2014; 15:580-591.
41. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE and Sequist LV. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012; 7:1602-1608.
42. Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ and Park K. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. British journal of cancer. 2013; 109:1482-1487.
43. Werner D, Atmaca A, Pauligk C, Pustowka A, Jager E and Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer medicine. 2013; 2:325-333.
44. Fury MG, Sherman E, Ho AL, Xiao H, Tsai F, Nwankwo O, Sima C, Heguy A, Katabi N, Haque S and Pfister DG. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 2013; 119:1823-1831.
45. Kumar P and Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2013; 6:35-43.
46. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001; 71:271-280.
47. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364:1595-1606.
48. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, et al. The autophagic tumor stroma model of cancer or "batteryoperated tumor growth": A simple solution to the autophagy paradox. Cell Cycle. 2010; 9:4297-4306.